Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Purchased by Bank of New York Mellon Corp

Bank of New York Mellon Corp boosted its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 2.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 359,045 shares of the biopharmaceutical company’s stock after acquiring an additional 8,330 shares during the period. Bank of New York Mellon Corp owned 0.34% of Intra-Cellular Therapies worth $29,987,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Wasatch Advisors LP grew its stake in shares of Intra-Cellular Therapies by 3.5% in the 3rd quarter. Wasatch Advisors LP now owns 3,848,588 shares of the biopharmaceutical company’s stock valued at $281,601,000 after buying an additional 130,351 shares during the period. Bellevue Group AG increased its position in shares of Intra-Cellular Therapies by 0.6% during the third quarter. Bellevue Group AG now owns 2,485,627 shares of the biopharmaceutical company’s stock valued at $181,873,000 after acquiring an additional 14,342 shares during the last quarter. State Street Corp raised its stake in shares of Intra-Cellular Therapies by 3.1% in the 3rd quarter. State Street Corp now owns 1,858,915 shares of the biopharmaceutical company’s stock valued at $136,017,000 after acquiring an additional 56,664 shares during the period. Franklin Resources Inc. lifted its holdings in shares of Intra-Cellular Therapies by 9.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,753,286 shares of the biopharmaceutical company’s stock worth $129,463,000 after acquiring an additional 155,655 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Intra-Cellular Therapies by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,708,301 shares of the biopharmaceutical company’s stock worth $125,029,000 after purchasing an additional 22,128 shares during the period. Institutional investors and hedge funds own 92.33% of the company’s stock.

Analyst Upgrades and Downgrades

ITCI has been the subject of several research analyst reports. Cantor Fitzgerald upgraded Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 14th. Mizuho cut Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $140.00 to $132.00 in a report on Monday, February 24th. Needham & Company LLC reaffirmed a “hold” rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. Baird R W cut shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Finally, Canaccord Genuity Group cut shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and lifted their price objective for the company from $119.00 to $132.00 in a report on Friday, January 31st. Ten investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Intra-Cellular Therapies has a consensus rating of “Hold” and an average price target of $106.08.

Intra-Cellular Therapies Price Performance

Intra-Cellular Therapies stock opened at $131.24 on Friday. The company has a market cap of $13.95 billion, a PE ratio of -150.85 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a 12 month low of $63.30 and a 12 month high of $131.36. The company has a fifty day moving average price of $119.20 and a two-hundred day moving average price of $93.55.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The firm had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. Equities research analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.